46412
17-醋酸甲羟孕酮
VETRANAL®, analytical standard
别名:
17α-乙酰氧基-6α-甲基孕酮, 17α-羟基-6α-甲基-4-孕烯-3,20-二酮 17-乙酸酯, 6α-甲基-17α-羟基孕酮乙酸酯, 6α-甲基-17α-羟孕酮醋酸酯
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式（希尔记法）:
C24H34O4
化学文摘社编号:
分子量:
386.52
UNSPSC Code:
41116107
NACRES:
NA.24
PubChem Substance ID:
EC Number:
200-757-9
Beilstein/REAXYS Number:
2066112
MDL number:
grade
analytical standard
Quality Level
product line
VETRANAL®
shelf life
limited shelf life, expiry date on the label
technique(s)
HPLC: suitable, gas chromatography (GC): suitable
mp
206-207 °C (lit.)
application(s)
pharmaceutical (small molecule)
format
neat
SMILES string
[H][C@@]12C[C@H](C)C3=CC(=O)CC[C@]3(C)[C@@]1([H])CC[C@@]4(C)[C@@]2([H])CC[C@]4(OC(C)=O)C(C)=O
InChI
1S/C24H34O4/c1-14-12-18-19(22(4)9-6-17(27)13-21(14)22)7-10-23(5)20(18)8-11-24(23,15(2)25)28-16(3)26/h13-14,18-20H,6-12H2,1-5H3/t14-,18+,19-,20-,22+,23-,24-/m0/s1
InChI key
PSGAAPLEWMOORI-PEINSRQWSA-N
Gene Information
human ... PGR(5241)
Application
Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.
Legal Information
VETRANAL is a registered trademark of Merck KGaA, Darmstadt, Germany
Still not finding the right product?
Explore all of our products under 17-醋酸甲羟孕酮
signalword
Warning
hcodes
Hazard Classifications
Aquatic Chronic 4 - Carc. 2
存储类别
11 - Combustible Solids
wgk
WGK 3
ppe
dust mask type N95 (US), Eyeshields, Gloves
法规信息
涉药品监管产品
此项目有
Jeong-Yeol Park et al.
Obstetrics and gynecology, 121(1), 136-142 (2012-12-25)
To analyze pregnancy outcomes in young women with stage IA, grade 1 endometrioid adenocarcinoma of the uterus after successful fertility-sparing management using progestin. We reviewed the medical records of 141 women with stage IA, grade 1 endometrioid adenocarcinoma of the
JoAnn E Manson et al.
JAMA, 310(13), 1353-1368 (2013-10-03)
Menopausal hormone therapy continues in clinical use but questions remain regarding its risks and benefits for chronic disease prevention. To report a comprehensive, integrated overview of findings from the 2 Women's Health Initiative (WHI) hormone therapy trials with extended postintervention
Robert A Wild et al.
Menopause (New York, N.Y.), 20(3), 254-260 (2013-02-26)
Our objective was to determine whether metabolic syndrome (MetS) or its components modified the effect of hormone therapy (HT) on the risk of coronary heart disease (CHD) events in the Women's Health Initiative clinical trials. We performed a nested case-control
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| 46412-250MG | 04061835560738 |